NewLink Genetics (NLNK) Sees Strong Trading Volume

NewLink Genetics Corp (NASDAQ:NLNK) shares saw strong trading volume on Wednesday . 2,266,720 shares were traded during trading, an increase of 553% from the previous session’s volume of 347,006 shares.The stock last traded at $1.81 and had previously closed at $1.60.

Several equities research analysts recently weighed in on the company. Zacks Investment Research raised NewLink Genetics from a “hold” rating to a “strong-buy” rating and set a $2.50 price target for the company in a report on Wednesday, November 7th. Bank of America decreased their price target on NewLink Genetics from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, November 2nd. Finally, ValuEngine raised NewLink Genetics from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company’s stock. NewLink Genetics presently has an average rating of “Hold” and an average target price of $4.75.

The firm has a market capitalization of $68.86 million, a price-to-earnings ratio of -0.71 and a beta of 1.89.

Large investors have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new position in NewLink Genetics in the third quarter worth $244,000. Renaissance Technologies LLC raised its position in NewLink Genetics by 125.8% in the second quarter. Renaissance Technologies LLC now owns 405,100 shares of the biotechnology company’s stock worth $1,928,000 after acquiring an additional 225,668 shares in the last quarter. Vanguard Group Inc raised its position in NewLink Genetics by 9.3% in the third quarter. Vanguard Group Inc now owns 1,614,773 shares of the biotechnology company’s stock worth $3,860,000 after acquiring an additional 136,947 shares in the last quarter. Dimensional Fund Advisors LP raised its position in NewLink Genetics by 432.1% in the third quarter. Dimensional Fund Advisors LP now owns 286,338 shares of the biotechnology company’s stock worth $684,000 after acquiring an additional 232,530 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in NewLink Genetics by 11.9% in the third quarter. Acadian Asset Management LLC now owns 289,092 shares of the biotechnology company’s stock worth $691,000 after acquiring an additional 30,634 shares in the last quarter. Hedge funds and other institutional investors own 35.33% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.themarketsdaily.com/2019/02/23/newlink-genetics-nlnk-sees-strong-trading-volume.html.

NewLink Genetics Company Profile (NASDAQ:NLNK)

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.

Read More: Dividend Achievers

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply